Department of Hematology and Oncology, Xiangyang NO.1 People's Hospital, Hubei University of Medcine, Xiangyang City, Hubei Province, China.
Oncology Department, Xiangyang NO.1 People's Hospital, Hubei University of Medcine, Xiangyang City, Hubei Province, China.
Eur Arch Otorhinolaryngol. 2022 Aug;279(8):4023-4032. doi: 10.1007/s00405-022-07363-1. Epub 2022 Apr 9.
This study aims to reveal changes in the incidence and prognosis of patients with tonsillar lymphoma on a population level.
The incidence, clinicopathological, and prognostic data of tonsillar lymphoma patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The Join-point software and R packages were utilized to analyze the annual percentage changes (APCs) and survival outcomes.
The incidence of primary tonsillar lymphoma increased from 0.1204 per 100,000 person-years (95% CI, 0.0680-0.1962) in 1983 to 0.2158 (95% CI, 0.1675-0.2740) in 2015 with an APC of 1.20. When classified by decades, both cancer-specific survival (CSS) and overall survival (OS) improved with time. The 2006-2015 decade showed the highest rate of CSS and OS. Nevertheless, for disease-specific survival (DSS), the difference was not significant between 1996-2005 and 2006-2015 decades. The main cause of mortality among this cohort was heart diseases. Three nomograms were constructed to predict OS, CSS, and DSS for patients with primary tonsillar lymphoma, respectively. Histological subtype made the most contribution to poor prognosis in OS-predicting and CSS-predicting nomograms. While, for DSS, age at diagnosis made the most contribution to poor outcomes.
The incidence of primary tonsillar lymphoma has increased in the past decades. The OS and CSS rates of tonsillar lymphoma improved continuously, while there was no significant improvement in DSS in the past decades. These changes indicated an improved management of tonsillar lymphoma with newer therapeutic agents and the need of multi-disciplinary treatments to offset the future burden of noncancer diseases.
本研究旨在揭示人群中扁桃体淋巴瘤患者发病率和预后的变化。
从监测、流行病学和最终结果(SEER)数据库中提取扁桃体淋巴瘤患者的发病率、临床病理和预后数据。使用 Join-point 软件和 R 包分析年度百分比变化(APC)和生存结果。
原发性扁桃体淋巴瘤的发病率从 1983 年的 0.1204/100,000 人年(95%CI,0.0680-0.1962)增加到 2015 年的 0.2158(95%CI,0.1675-0.2740),APC 为 1.20。按十年分类,癌症特异性生存率(CSS)和总生存率(OS)均随时间改善。2006-2015 十年 CSS 和 OS 率最高。然而,对于疾病特异性生存率(DSS),1996-2005 年与 2006-2015 年十年之间差异无统计学意义。该队列的主要死亡原因是心脏病。构建了三个列线图分别预测原发性扁桃体淋巴瘤患者的 OS、CSS 和 DSS。组织学亚型对 OS 预测和 CSS 预测列线图的预后不良影响最大。然而,对于 DSS,诊断时的年龄对不良结局的影响最大。
过去几十年原发性扁桃体淋巴瘤的发病率有所增加。扁桃体淋巴瘤的 OS 和 CSS 率持续提高,而过去几十年 DSS 无显著改善。这些变化表明,随着新型治疗药物的应用以及多学科治疗的需要,能够改善扁桃体淋巴瘤的管理,以抵消未来非癌症疾病的负担。